Orthofix Medical Inc 8-K, filed Oct 3, 2023
Orthofix Medical Inc. (OFIX)
About this 8-K
Orthofix Medical Inc filed this 8-K on October 3, 2023, reporting on events of September 27, 2023.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 |
Departure of Directors of Principal Officers; Election of Directors; Appointment of Principal Officers. |
Compensation Arrangements with Interim Chief Financial Officer
On September 27, 2023, the Compensation and Talent Development Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Orthofix Medical Inc. (the “Company”) approved new compensation arrangements for Geoffrey C. Gillespie, the Company’s Interim Chief Financial Officer. Under these arrangements, Mr. Gillespie will receive (i) an updated base salary amount of $290,000, and, with respect to the portion of the 2023 calendar year occurring on and after September 12, 2023 (the date his service as Interim Chief Financial Officer began), and an updated target annual incentive program bonus equal to 70% of the amount of base salary accrued from and after such date, and (ii) an interim monthly stipend of $12,500 per month during such time period as Mr. Gillespie serves as Interim Chief Financial Officer. Effective as of the close of business on October 15, 2023, Mr. Gillespie has been granted restricted stock units (“RSUs”) with a fair market value of $290,000. Such RSUs will vest in full in one installment on the second anniversary of the grant date.
The Compensation Committee also approved Mr. Gillespie entering into a severance agreement with the Company, which the parties entered into on October 3, 2023. Under the terms of the severance agreement, if Mr. Gillespie’s employment is terminated by the Company without “cause” or by Mr. Gillespie for “good reason,” in each case during the period that he serves as the Company’s Interim Chief Financial Officer and for one year thereafter, then Mr. Gillespie will be entitled to receive (i) a pro rata bonus for the year of termination of employment, deemed achieved at a 100% performance level, and (ii) severance in an amount equal to the sum of his annual base salary and current year’s target bonus (such severance being conditioned upon the signing of a release of claims). In the event that Mr. Gillespie remains employed with the Company one year following the end of his service as Interim Chief Financial Officer, the agreement will expire at such time.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Orthofix Medical Inc. |
|
||
By: |
|
/s/ Puja Leekha |
|
|
|
Puja Leekha Senior Vice President, Chief Ethics and Compliance Officer and Interim Chief Legal Officer |
|
Date: October 3, 2023